MONTGOMERY COUNTY, Md. (WDVM) — BioNTech announced that they will soon be joining Montgomery County’s growing list of world-renowned international companies in the “Immunology Capital Next to the Nation’s Capital.”
The German-based company is acquiring a manufacturing facility and cell therapy R&D platform from Kite. The company has been working with Pfizer on the widely distributed COVID-19 vaccine. At this new facility, BioNTech is looking to increase their cell therapy production to support more cancer clinical trials.
Benjamin H. Wu, President & CEO of the Montgomery County Economic Development Corporation (MCDED) says this move signals the county’s growing maturation as a world immunology
“To see Montgomery County companies helping to develop these cures and treatments, but also more recently to be able to see how they are helping to support COVID-19 vaccines, and bringing us a sense of normalcy… it brings us a lot of pride,” said Wu.
The BioNTech and Kite transaction is expected to close by the end of July 2021.